Amphotericin B colloidal dispersion (ABCD, AMPHO-TEC, AMPHOCIL), a lipid complex of amphotericin B, was developed to reduce the nephrotoxicity of amphotericin B while retaining its antifungal efficacy. In this retrospective review, the efficacy and safety of ABCD were evaluated in 220 BMT recipients (167 allogeneic; 53 autologous) with suspected or documented lifethreatening fungal infections (primarily Candida or Aspergillus species). Patients were treated in five openlabel clinical trials of ABCD therapy. ABCD was administered intravenously once daily, median dose of 4 mg/kg, for up to 409 days (mean 23 days, median 16 days). Successful therapeutic response to treatment (complete or partial) was reported in 52% of the 99 evaluable patients with proven infection, and in 40% of all 220 patients. In the evaluable population, the response and mortality rates were 51% and 73%, respectively, in the allogeneic BMT patients, compared to 52% and 48% in the autologous BMT patients. The response rate for evaluable patients with Candida spp was 65%, 38% for patients with Aspergillus spp, and 42% for patients with other or multiple fungal infections. In this patient population at high risk of nephrotoxicity due to concomitant cyclosporine and/or other nephrotoxic agents, ABCD did not cause renal dysfunction. Although the majority of patients had pre-existing renal impairment (median baseline serum creatinine 1.8 mg/dl), there was no trend towards increasing serum creatinine. No unexpected toxicities were observed. In conclusion, ABCD appears to be safe and effective for the treatment of severe fungal infections in BMT patients. Keywords: ABCD; amphotericin B cholesteryl sulfate for injection; amphotericin B colloidal dispersion; marrow transplant; fungal infection; nephrotoxicity Opportunistic fungal infections are an increasing cause of morbidity and mortality in bone marrow transplant (BMT) patients. evolved, the problem of invasive fungal infection has assumed increased significance. In reports from marrow transplant centers 1-3 the incidence of systemic fungal infections ranges from 4 to 30% with a mortality rate approaching 100%. 4 The administration of prophylactic fluconazole may decrease the incidence of documented systemic fungal infection following high-dose chemotherapy and BMT. 5, 6 However, despite fluconazole prophylaxis, over half of patients still require empiric therapy with amphotericin B for prolonged unexplained febrile episodes.
evolved, the problem of invasive fungal infection has assumed increased significance. In reports from marrow transplant centers [1] [2] [3] the incidence of systemic fungal infections ranges from 4 to 30% with a mortality rate approaching 100%. 4 The administration of prophylactic fluconazole may decrease the incidence of documented systemic fungal infection following high-dose chemotherapy and BMT. 5, 6 However, despite fluconazole prophylaxis, over half of patients still require empiric therapy with amphotericin B for prolonged unexplained febrile episodes. 5 Additionally, fluconazole is not effective against Aspergillus spp infections and certain species of Candida, such as C. krusei and most strains of C. glabrata.
Amphotericin B, a polyene antibiotic that has been used to treat fungal infections for four decades, is still considered the most reliable agent for therapy of mycoses in immunosuppressed patients. However, its well known adverse effects, particularly dose-limiting nephrotoxicity, often complicate and limit its effective use. 7 Although the reported incidence is quite variable, two recent reviews estimate that 60% 8 and 80% 9 of patients develop amphotericin B-related renal impairment, which can be either irreversible or last months after the completion of therapy. Renal impairment is a major concern in the BMT setting because the primary agents used for immunosuppression to prevent graft-versus-host disease (GVHD), cyclosporine and tacrolimus, are also nephrotoxic. Attempts to moderate the drug's toxicity through alternate-day dosing or dose reduction can result in inadequate drug levels and possible therapeutic failure.
Amphotericin B colloidal dispersion (ABCD, also known as AMPHOTEC, AMPHOCIL, Amphotericin B cholesteryl sulfate complex for injection; SEQUUS Pharmaceuticals, Menlo Park, CA, USA) is a formulation of amphotericin B developed to reduce the nephrotoxic effects associated with conventional amphotericin B while maintaining its efficacy. ABCD is a high-affinity lipid complex consisting of amphotericin B and sodium cholesteryl sulfate in a near 1:1 molar ratio. The pharmacokinetic profile of the ABCD complex avoids the immediate high peak serum concentrations of amphotericin B and high renal tissue uptake that occur when amphotericin B deoxycholate is administered, while still subsequently providing serum levels of amphotericin B similar to the levels achieved by conventional amphotericin B. As a result, ABCD is less nephrotoxic than amphotericin B, but has similar in vitro and in vivo antifun-gal activity, similar clinical efficacy, and a similar safety profile with the exception of reduced nephrotoxicity. [10] [11] [12] [13] ABCD has been shown to be significantly less toxic than conventional amphotericin B in animals, without reduction in efficacy, permitting administration of higher doses. 14, 15 In experimental infections, laboratory animals responded to ABCD and conventional amphotericin B at similar rates, but safety was demonstrated at ABCD doses that were five to eight times higher than doses of conventional amphotericin B. 16 In clinical trials, ABCD has been shown to be safe and well tolerated. In a historical control study comparing ABCD-treated aspergillosis patients with similar patients given amphotericin B at six cancer or transplant centers from January 1990 to June 1994, response (49%) and survival (50%) rates for ABCD-treated patients were significantly higher than those for amphotericin B-treated patients (23% and 28%, respectively), with significantly less nephrotoxicity (8% vs 43%). 17 In a dose-escalation tolerance study of 75 BMT recipients with documented or suspected fungal infections, Bowden et al 18 reported clinical improvement with ABCD in 52% of 75 BMT patients with no appreciable nephrotoxicity observed in patients treated with ABCD at doses of up to 8 mg/kg/day. The most common adverse events were infusion-related, similar to those seen with amphotericin B, and generally self-limiting. Similarly, in a study comparing ABCD to amphotericin B in the treatment of febrile neutropenic patients, in which approximately 70% of the patients were BMT recipients, ABCD demonstrated comparable efficacy compared to amphotericin B, with significantly less nephrotoxicity (20% of ABCD patients compared to 52% of amphotericin B patients experienced renal toxicity). 12 In order to assess the relative efficacy and renal safety of ABCD in BMT patients, we conducted a retrospective review of 572 patients with documented or suspected fungal infections who were treated with ABCD in five openlabel trials. Most patients in these trials were either unable to tolerate amphotericin B, due to pre-existing or amphotericin B-induced nephrotoxicity, or had failed to respond to amphotericin B, although 75 patients were BMT recipients in a dose-escalation tolerance study where amphotericin B intolerance or failure was not an entry criterion. Of these 572 patients, 220 were identified as BMT patients. Here, we present efficacy and safety for this subset of 220 BMT patients treated with ABCD in these open studies.
Patients and methods

Patient population
The clinical data for 572 patients enrolled in five open-label ABCD trials from November 1991 to June 1994 at 42 sites were reviewed. 13, 18, 19 From this database, the clinical data for all patients who were BMT recipients with suspected or documented systemic fungal infection were selected for this analysis.
Four of the five open-label trials were multicenter, conducted at sites in the United States, and, for one study, included European sites. Patients enrolled into these trials had either developed nephrotoxicity due to amphotericin B or another nephrotoxic agent, had pre-existing renal insufficiency, or had failed prior treatment with conventional amphotericin B, defined as у15 mg/kg or у7 days of therapy without improvement, or had a new locus of infection. Patients were excluded from these studies if they had an allergy to amphotericin B, were under 2 years of age, had hepatic precoma or coma, were pregnant or lactating, or had a hemoglobin level Ͻ7 g/dl. The daily dose of ABCD administered to patients in these trials varied according to the individual protocols, ranging from 2 to 6 mg/kg/day. Therapy was scheduled to last 2 weeks after the disappearance of signs and symptoms of fungal infection or for up to 6 weeks. Fungemia was an exception, with a proposed treatment duration of 1 week after the disappearance of signs and symptoms of infection, provided that neutropenia had resolved. The fifth trial was a single-center, dose-escalation maximum tolerated dose (MTD) study of ABCD in BMT recipients with invasive fungal infection. Patients in this trial received ABCD in daily doses ranging from 0.4 to 8 mg/kg, with 7.5 mg/kg estimated to be the maximum tolerated dose. 18 Details of the five trials are described briefly in Table 1 .
Definition of infection
Fungal infections were classified as definite (proven or probable) or insufficient evidence. Classification was based on general clinical and mycologic criteria from the diseasespecific guidelines of the Infectious Diseases Society of America and the FDA. 20 For endemic mycoses, compatible clinical findings and isolation of the pathogen from any source were sufficient to classify the infection as definite. A positive cryptococcal antigen was considered evidence of definite infection, as was isolation of opportunistic fungi from biopsy specimens or from normally sterile body fluids or sites. Patients with radiographic evidence of pulmonary infection and isolation of opportunistic fungi from one bronchopulmonary alveolar lavage specimen or two sputum specimens were considered to have definite infection.
Definition of response
Therapeutic efficacy was determined for evaluable patients with proven infection by both clinical and mycologic responses. Clinical evaluation included signs and symptoms, radiographic changes, and histopathologic findings from biopsies or postmortem examinations. Mycologic evaluation was based on results of cultures, fungal antigen/antibody studies and other microbiologic tests, such as nucleic acid probes. Response to treatment was rated by the investigator as one of the following:
Complete response: No clinical or mycologic evidence of active infection; complete resolution of involved site at the end of therapy.
Partial response: Improvement in signs of disease activity but all criteria for Complete response were not satisfied. Baseline was defined as the first day of ABCD treatment. 
Toxicity
Toxicity was determined by investigator assessment.
Patients were monitored daily for adverse events and had regular (at least weekly) clinical laboratory assessment. The development of renal toxicity while on treatment was defined as either a doubling of serum creatinine from baseline, an increase of 1 mg/dl from baseline or at least a 50% decrease in calculated creatinine clearance. Investigators were required to describe deaths during the study in brief narrative form, including comments on the possible relationship to the study drug.
Results
Patient characteristics
Safety and efficacy were assessed for all 220 BMT patients (intent-to-treat group), even if they had insufficient evidence of infection at baseline or had discontinued treatment within the first week of the study. In addition, efficacy was assessed for an evaluable patient subgroup using more stringent criteria. Patients considered evaluable for efficacy were required to meet the following three criteria: definite fungal infection at baseline, received ABCD for at least 7 of the first 10 days on treatment, and had received no concurrent systemic antifungal treatment.
Of the 220 BMT patients (167 allogeneic, 53 autologous), 114 (52%) were male and 106 (48%) female, and the majority (83%) were white ( Table 2 ). They ranged in age from 2 to 62 (median: 36) years with the majority of patients being older than 13 years (199 patients, 91%). In the intent-to-treat population, 61 (27.7%) patients had received fluconazole within 1 week prior to study entry. The median daily dose of ABCD was 4.0 mg/kg, ranging from 0.4 to 8.0 mg/kg. The median total dose was 60.0 mg/kg (range 1.4 to 1378 mg/kg). The median duration of treatment was 16 days, ranging from 1 to 409 days. One hundred (45%) patients were infected with Candida spp, 68 (31%) with Aspergillus spp, and 52 (24%) with other fungi. The baseline characteristics of the 99 patients who qualified for inclusion in the evaluable patient group were similar to the intent-to-treat population, with the exception of longer duration of treatment inherent in the 
Response
Of the 99 patients in the evaluable group, 51 (52%) achieved a successful therapeutic response (either a complete Table  3 ). The overall response rate for evaluable patients was 51% (40/78) in the allogeneic BMT recipients and 52% (11/21) in the autologous BMT patients. Eighty-nine (40%) of the 220 intent-to-treat patients achieved a successful therapeutic response, with a rate of 38% (63/167) in the allogeneic BMT patients and 49% (26/53) in the autologous BMT patients.
Response was not related to the daily dose, although an increased response rate was seen in those patients who were able to receive total doses of у70 mg/kg ( Table 4 ). The response rate was 28% (11/39) in patients receiving Ͻ70 mg/kg compared to 67% (40/60) for patients receiving у70 mg/kg, and, in the intent-to-treat population, 19% (23/121) compared to 67% (66/99).
Among the evaluable patients, absolute neutrophil counts were available at baseline and end of treatment for 81 (82%) of the 99 patients. The overall response rate for patients with neutropenia at baseline was 32% (8/25) compared to 59% (33/56) for nonneutropenic patients.
Response was related to duration of therapy and PMN counts. Patients who received Ͼ14 days of therapy and had PMN counts Ͼ500 at the end of therapy had the highest response rate. Among the evaluable patients who received Ͻ14 days of therapy, 14% (1/7) responded in those patient with PMN counts Ͻ500 at the end of therapy; 31% (5/16) responded in those patients with PMN counts Ͼ500 at the end of therapy. For evaluable patients who received Ͼ14 days of therapy, 33% (3/9) of patients with PMN counts Ͻ500 at the end of therapy responded compared to 65% Table 4 Response rates by fungal organism and dose -evaluable patients
Candidiasis Aspergillosis
Other Total (32/49) in patients with PMN counts Ͼ500 at the end of therapy. In the intent-to-treat population, the response rate for patients receiving Ͻ14 days of therapy was 10% (2/20) for patients with PMN counts Ͻ500 at the end of therapy, and 22% (9/41) for patients with PMN counts Ͼ500 at the end of therapy. For the intent-to-treat patients who received Ͼ14 days of therapy, 27% (4/15) for those patients with PMN counts Ͻ500 at the end of therapy responded compared to 62% (52/84) of patients with PMN counts Ͼ500 at the end of therapy.
Mortality
The overall mortality rate in the intent-to-treat population was 70% (153/220). The overall mortality rate for evaluable patients was 68% (67/99); the mortality rate was 54% (25/46) for patients with Candida spp, 79% (27/34) for patients with Aspergillus spp, and 79% (15/19) for patients with other or multiple fungal infections. Not surprisingly, the mortality was higher among allogeneic BMT patients than in autologous BMT patients (73% vs 59% in the intent-to-treat population and 73% vs 48% in the evaluable patients). Ten percent of the evaluable population (15% of the deaths) died of fungal infection. One patient's death was considered by the investigator to be possibly related to the administration of ABCD. The patient, a 34-year-old man who received ABCD for 25 days for treatment of pulmonary aspergillosis, died of Pseudomonas sepsis 1 week after discontinuation of ABCD. He had developed lethargy, leading to a coma that necessitated artificial ventilation 3 days prior to end of treatment. The postmortem, which did not include examination of the brain, did not reveal a cause for the coma. Since the investigator thought the unexplained CNS symptoms were possibly related to ABCD, and the sepsis was secondary to the patient being placed on a ventilator, the death was recorded as possibly related.
Safety
ABCD did not appear to cause renal dysfunction in this patient population as measured by a variety of different measures. Allogeneic BMT patients, most of whom received concurrent cyclosporine, had little change in serum creatinine from baseline; similar values were noted in the autologous BMT patients. Thirty-seven (19.2%) patients experienced renal toxicity. Twenty-five (21.4%) of the 117 patients who received cyclosporine or tacrolimus experienced renal toxicity compared to 12 (15.8%) of the 76 patients who did not (Table 5) . Evaluation of renal function as measured by the calculated creatinine clearance showed stabilization for those allogeneic patients who were treated with concurrent cyclosporine or tacrolimus and improvement in the other patients (Table 6 ). There was no significant hepatotoxicity associated with ABCD. There was little change from baseline in total bilirubin, SGOT and alkaline phosphatase (mean baseline values and mean change from baseline values were 4.71 mg/dl and 5.31 mg/dl, 62.9 U/l and 14.1 U/l and 221.3 U/l and 42.5 U/l, respectively).
Severe, possibly or probably related adverse events 701 Table 5 Proportion of patients developing renal toxicity classified by cyclosporine/aminoglycoside usage during therapy -all patients dosed Renal toxicity is defined as either a doubling of serum creatinine from baseline, an increase of 1 mg/dl from baseline or at last a 50% decrease in calculated creatinine clearance. Cyclosporine usage includes the use of tacrolimus (FK-506). reported by 5% or more of patients included fever and chills, reported by 27 (12.3%) and 23 (10.5%) patients, respectively. Other acute, severe infusion-related adverse events were hypoxia (4.1%), hypertension (2.7%) and hypotension (2.7%). There were no unexpected toxicities seen (that is, adverse events not associated with amphotericin B or the underlying diseases).
Discussion
The increasing use of BMT as treatment for neoplastic diseases has led to a greater population of immunosuppressed patients, and with that, a concurrent increase in the number of fungal infections. The increased incidence of systemic fungal infections seen in BMT recipients is attributed to the intense treatments these patients receive, such as aggressive antineoplastic chemotherapy and immunosuppressive medications used to prevent GVHD. Other factors that lead to an increased risk of fungal infection include prolonged neutropenia, impaired host defense mechanisms as a consequence of their diseases, use of broad-spectrum antibiotics, the development of GVHD, hyperalimentation, extended periods of hospitalization, and the disruption of skin integrity by indwelling vascular catheters. 21, 22 All of these conditions enhance fungal colonization and alter host defense mechanisms, making opportunistic fungal infections a significant cause of morbidity and mortality in these patients.
Although new azole agents, such as itraconazole and fluconazole, have demonstrated clinical utility, amphotericin B remains the treatment of choice for serious or lifethreatening invasive fungal infection. However, due to its nephrotoxicity it may be difficult to balance the use of other nephrotoxic agents required to prevent GVHD or treat bacterial or viral infection and give sufficient therapy to cure the infection.
This study describes the largest cohort of BMT patients with systemic fungal infections treated with ABCD published to date, with a cohort size comparable to similar retrospective analyses of patients treated with conventional amphotericin B. The goal of our retrospective analysis was to evaluate the safety and efficacy of ABCD, a lipid-based formulation of amphotericin B, in BMT patients. This analysis demonstrated that ABCD was safe and effective in the treatment of fungal infection in BMT recipients. Denning 23 conducted an extensive review of the published literature to summarize the available data for the treatment of invasive aspergillosis. For BMT patients, no patient who had received less than 14 days of conventional amphotericin B therapy responded. For those patients who received у14 days of treatment, the response rate was 33% (5/15) . This response rate is comparable to the observed response rate of 35% (12/34) in this study. The overall response rate for aspergillosis in the intent-to-treat population was 28% (19/68) in this study.
The overall mortality rate in this study for patients with aspergillosis was 78% (53/68), which is similar to rates previously reported. Morrison and colleagues 24 reviewed a consecutive series of 1186 patients who underwent BMT between 1974 and 1989 at the University of Minnesota. Only 10 of the 97 patients with Aspergillus infections survived, with an overall mortality of 90% (87/97). 24 These results are consistent with the data published by Meyers 22 conducted at Fred Hutchinson Cancer Research Center from 1980 to 1987 of over 1500 BMT patients (84% mortality rate for BMT patients with Aspergillus infection) and by Wald and colleagues 25 at the same center between 1987 and 1993 of 2496 BMT patients (93% mortality rate for the 158 patients with invasive aspergillosis).
Patients treated with ABCD for Candida infection had a higher response rate than those infected with Aspergillus, with 67% (31/46) of evaluable patients responding and 51% (51/100) of intent-to-treat patients having a complete or partial response. The mortality rate of patients with candidiasis was 61% (61/100), which is comparable with previous observations.
